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Abstract
The evaluation of clinical tumor tissues is a
valuable approach to discovering novel drug
targets because of the direct relevance of human
samples. We used activity-based proteomic pro-
filing (ABPP) to study the differences in serine
hydrolase activities from 12 matched pairs of
clinical normal and tumor colon tissues. Unlike
traditional proteomics or measures of mRNA
abundance, ABPP actually quantifies enzymatic
activities, a characteristic crucial for drug target-
ing. Several serine hydrolases were differentially
active in tumor vs normal tissues, despite a lack
of obvious corresponding alterations in protein
expression. We identified one tumor-specific
activity by mass spectrometry to be fibroblast
activation protein (FAP), an integral membrane
serine protease that has been reported to be pre-
sent only in tumor stroma or during wound
healing and absent in normal tissues. FAP activ-
ity was further found to be approximately
twofold higher in stage III relative to stage II
colon cancer, suggestive of a role in tumor pro-
gression. We were also able to identify other
proteins, some of which had not been previ-
ously linked to cancer, which had higher activity
in tumors. Our results demonstrate the applica-
bility of ABPP for the efficient identification of
multiple clinical disease targets.
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Introduction
The lifetime probability of developing
cancer is one in two for men and one in three
for women (1). As cancer remains the second
leading cause of death behind heart disease,
the search for novel drug targets continues.
Common methods for evaluating normal 
vs tumor tissues include two-dimensional 
(2-D) gel electrophoresis and microarray,
which measure protein and mRNA levels,
respectively. These approaches search for dif-
ferences on a global scale; however, mRNA
levels do not always correlate to protein abun-
dance, and protein abundance does not
always reflect enzyme activity. Zymogen pro-
forms, inhibitors, and protein-protein interac-
tions can all regulate enzymatic activity. In
order to increase the probability of finding a
druggable cancer target, one approach is to
find the differences in the “business end” of
proteins, that is, in the protein activities that
are upregulated in tumor tissues.
Here, we present an activity-based pro-
teomic profiling (ABPP) approach for drug
target discovery in clinical colorectal car-
cinoma. We used a fluorescently tagged, 
activity-based chemical probe to comprehen-
sively scan the large serine hydrolase super-
family. This family comprises 1000 members
and includes proteases, lipases, esterases, and
amidases, among others. In addition, there are
still many serine hydrolases whose functions
are unknown. The advantage of the ABPP
method is that one can use crude tissue lysates
to rapidly scan for and quantify alterations in
protein activities. Other advantages over tra-
ditional protein screening methods include the
requirement for only small quantities of tissue
(20 g is used per gel lane), high sensitivity
(low femtomole levels of active protein can be
detected) (2), and the ability to study both sol-
uble and membrane protein activities. These
conditions are well suited for evaluating clin-
ical tissue specimens, which are frequently of
limited quantities but provide the most rele-
vant source of human disease targets.
From the analysis of 12 pairs (tumor and
adjacent normal) of clinical colon tissues, we
found the activities of 12 of 22 soluble serine
hydrolases and 3 of 22 membrane serine
hydrolases to be significantly increased in
tumor vs normal tissues. In contrast, three
proteins in the membrane fraction had signif-
icantly decreased activity. Following mass
spectrometry identification, a number of pro-
teins were found that had previously been
studied in relation to cancer. Fibroblast ac-
tivation protein (FAP) was one such tumor-
specific activity, and, interestingly enough, 
by using ABPP we found a trend of increased
FAP activity with more advanced tumors. We
also report the identification of other protein
activities that had not been previously linked
with cancer, such as the intracellular isoforms
of platelet activating factor acetylhydrolase
(PAF-AH), phospholipases with emerging
roles in inflammatory disease. The identifica-
tion of cancer-associated proteins validates
ABPP as a rapid means of tumor target dis-




Matched primary tumors and adjacent
normal colon tissues from 12 patients diag-
nosed with colorectal adenocarcinoma were
selected from samples residing in the Global
RepositoryTM at Genomics Collaborative, Inc.
(Cambridge, MA). All samples were obtained
from human subjects with full informed con-
sent. The study set consisted of tumor and
normal tissue pairs from patients with stage II
(n = 6) and stage III (n = 6; lymph node
involvement) diagnoses. Staging was estab-
lished by pathologists at the site of collection
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and confirmed by pathologists at Genomics
Collaborative Inc. The median percentage of
carcinoma in the tumor tissues was 78%, with
0% in the normal tissues. Following procure-
ment from surgical specimens, tissues were
flash frozen and stored in liquid nitrogen until
used.
Tissues were processed by crushing them
into approx 1-mm pieces under liquid nitro-
gen, using a ceramic mortar and pestle. Ap-
proximately 50–100 mg wet weight of each
tissue was homogenized in 50 mM Tris buffer
at pH 7.4, using an Omni mechanical homog-
enizer (Omni International, Warrenton, VA).
Each lysate was briefly sonicated and the
unlysed material was pelleted by centrifuga-
tion at 1100g for 15 min. The crude super-
natant was then subjected to centrifugation at
110,000g for 1 h at 4°C. The resultant high-
speed supernatant containing cytosolic pro-
teins was collected as the soluble fraction. The
membrane pellet was solubilized by soni-
cation in 50 mM Tris buffer at pH 7.4 with
0.1% Triton X-100. Protein concentrations were
assayed using the Dc protein kit (Bio-Rad Lab-
oratories, Hercules, CA). Approximately 1 and
1.5% of the original tissue weight were recov-
ered in the soluble and membrane protein
fractions, respectively.
Proteome Labeling and Analysis
The fluorophosphonate TAMRA (AX5070)
probe was synthesized as previously de-
scribed (2) and was solubilized in dimethyl
sulfoxide (DMSO). To label tissue lysates, we
added AX5070 probe to each tissue lysate (1
mg/mL) to a final concentration of 2 M and
incubated it for 1 h at 25°C. One hour has
been shown to provide complete end-point
labeling. Final DMSO concentrations were
<5% of total volume. Membrane proteomes
were deglycosylated with PNGase F (New
England Biolabs, Beverly, MA) after probe
labeling in order to sharpen bands and to get
baseline molecular weights. Reactions were
quenched by adding an equal volume of 2
reducing SDS-PAGE loading buffer and heat-
ing at 95°C for 5 min. Equal protein amounts
(20 g/lane) were loaded onto 12% SDS-
PAGE gels. Gels were directly scanned for
fluorescence using a 605-nm bandpass filter
for detection on the Hitachi FMBIO IIe
(Miraibio, Alameda, CA). Fluorescence was
measured using the accompanying Image-
Analysis software for each distinct activity
band on the gel and expressed as fluores-
cence volume units.
Protein Identification
Tissue lysates (1–3 mg) were labeled with
AX5070, subsequently denatured by heating to
65°C for 10 min with 8 M urea and 10 mM
dithiothreitol, and modified with 40 mM
iodoacetamide. The lysate was then applied to
a Bio-Rad PD10 gel exclusion column to elim-
inate excess free probe and to exchange the
buffer for 2 M urea and 20 mM ammonium
bicarbonate. The eluate was adjusted to con-
tain 1% SDS, and heated at 65°C for 5 min
before adding an equal volume of 2 binding
buffer (2% Triton X-100, 1% Tergitol type NP40,
300 mM NaCl, 2 mM EDTA, 20 mM Tris, pH
7.4). This was then incubated with Affi-Gel Hz
Hydrazide Gel (Bio-Rad) coupled to anti-
rhodamine monoclonal antibodies custom gen-
erated through Rockland Immunochemicals
(Gilbertsville, PA). The AX5070-labeled pro-
teins were eluted in nonreducing SDS-PAGE
loading buffer and resolved on SDS-PAGE.
After scanning for fluorescence, the protein
bands of interest were excised and prepared
for tryptic digestion. Peptides were analyzed
by nano-liquid chromatography/ tandem mass
spectrometry (LC/MS/MS), on a combina-
tion system of an Agilent 1100 capillary
HPLC/Micro Auto-sampler (Agilent Technolo-
gies, Palo Alto, CA) and an LCQ DecaXP ion
trap mass spectrometer (Thermo Finnigan, San
Jose, CA). Data generated were analyzed 
using the Mascot search engine for protein
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identification (Matrix Science, London, UK). A
positive protein identification was accepted
when the following criteria were all met: (1) At
least three peptides were assigned to the pro-
tein; (2) ranking of the ion match was 1 with
the mass error 1; and (3) the probability-
based Mowse score was 36 (p  0.05).
For some fluorescent protein bands, pep-
tides matching multiple proteins were found
by mass spectrometry. In order to narrow
down the identity of the major activity in the
band, specific inhibitors, if available, were
used in subsequent labeling studies. For those
studies, 20 g of tissue lysate was preincu-
bated with or without inhibitor at various con-
centrations for 15 min at room temperature.
The AX5070 probe was then used to label the
active serine hydrolases in the lysate. The pre-
vention of AX5070 labeling by a specific
inhibitor, seen as an absence of fluorescence
for the protein band on the gel, indicates the
protein’s identity. Specific inhibitors included
prolyl endopeptidase inhibitor (Calbiochem,
San Diego, CA), methyl arachidonyl fluoro-
phosphonate (phospholipase inhibitor; Cayman
Chemical, Ann Arbor, MI), and 1-O-palmitol-
2-(N-methylcarbamyl)-sn-glycero-3-phospho-
choline (nonhydrolyzable form of PAF; Sigma,
St. Louis, MO).
F19 Antibody and Western Blot
The F19 hybridoma cell line that produces
antibodies against human fibroblast activation
protein was obtained from the American Type
Culture Collection (ATCC, Manassas, VA) and
maintained in RPMI supplemented with 10%
fetal bovine serum. Monoclonal antibody F19
was affinity purified from F19 hybridoma-
conditioned media using protein A Sepharose.
Tissue lysates labeled with AX5070 were
run on SDS-PAGE, scanned for fluorescence,
and transferred to nitrocellulose. The blot was
blocked in 5% nonfat dried milk/TBS-T (50
mM Tris with 0.1% Tween-20) for 1 h at 25°C.
For the primary antibody incubation, blots
were incubated with monoclonal antibody F19
at 2 g/mL in 5% milk/TBS-T, 4°C overnight.
Following washes in TBS-T, the blot was incu-
bated with 1:5000 horseradish peroxidase-
conjugated goat anti-mouse secondary anti-
body (Pierce Chemical Co., Rockford, IL) in
5% milk/TBS-T for 1 h at 25°C. After washing,
the blot was developed in SuperSignal West
Pico Substrate (Pierce) and visualized using
the FluorChem imaging system (Alpha
Innotech Corp., San Leandro, CA).
Statistics
Normal and tumor samples were always
run and scanned on the same gel. The paired
student’s t-test was used to analyze the mean
fluorescence volume units of individual pro-
tein bands from normal and tumor tissues.
Significance was accepted if p  0.05 and if at
least two of three experiments were consistent
statistically.
Results
Serine Hydrolase Activities in Tumor 
and Normal Colon Tissues
The AX5070 probe was developed to selec-
tively react with the catalytic serine of the large
superfamily of serine hydrolase enzymes. This
activity-based chemical probe consists of a fluo-
rophosphonate reactive “warhead,” an alkyl
linker, and a fluorescent tetramethylrhodamine
(TAMRA) tag (Fig. 1). The probe covalently links
to active enzyme (but not to inactive versions
such as proenzyme, denatured protein, and
inhibited enzyme), thus allowing for an assess-
ment of the active enzymatic state of a complex
protein mixture (2,3). In any given sample, only
a subset of the total proteins is made up of serine
hydrolases, and only a portion of this subset is
active proteins that will bind to AX5070. There-
fore, as this process results in the fluorescent
tagging of only a portion of the proteome, the
AX5070-tagged proteins can be easily resolved
by one-dimensional SDS-PAGE and visualized
using a fluorescence scanner.
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The AX5070 probe was used to assess the
serine hydrolase activities in tissue samples
from patients with colorectal adenocarcinoma.
From the total of 12 paired (tumor and adja-
cent normal) tissues, 6 were from patients
with stage II cancer and 6 were from patients
with stage III cancer. Tissue lysates from each
patient were fractionated into soluble and
membrane fractions by high-speed centrifuga-
tion and labeled with AX5070. Equal amounts
of proteome were loaded onto SDS-PAGE gels.
After resolving the proteins, the gels were
scanned for fluorescence and each protein
band was quantified for fluorescence volume
as a measure of activity. Despite the expected
biological variance in enzyme activities among
patients, a number of protein bands were
found to display statistically significant differ-
ences in activity. In the soluble fraction, 12 of
22 fluorescent protein bands were significantly
upregulated in tumor vs normal tissues (Fig.
2A). In the membrane fraction, the fluores-
cence of three protein bands was significantly
increased, whereas that of three others was
significantly decreased in tumor relative to
normal tissue (Fig. 2B). Interestingly, the three
membrane protein activities that increased
had minimal probe labeling in normal tissues,
therefore appearing to be tumor specific.
Coomassie blue staining of the gels after fluo-
rescence scanning did not reveal obvious
accompanying changes in protein abundance
(Fig. 3A,B). This is not unexpected, because
activity-based probes are so sensitive that
enzyme activities can be easily seen below the
picomole range (equivalent to nanogram
amounts for a typical protein mass of 50 kDa),
which is close to the limit of detection for
Coomassie blue staining.
Protein Identifications and Activities
In order to identify the fluorescently la-
beled, active serine hydrolases from the pro-
teome, the AX5070-tagged proteins were
captured by immunoprecipitation using an
anti-rhodamine antibody in order to separate
them from nonlabeled proteins. The fluores-
cently labeled proteins were then resolved on
SDS-PAGE and the individual bands were
excised, digested with trypsin, and subjected
to peptide analysis by nano-LC/MS/MS.
Resultant peptide identities were searched out
using Mascot. For some protein bands, espe-
cially in the crowded 25- to 37-kDa molecular
weight range, peptides from multiple proteins
were identified within a single band and it
was not clear which of the proteins were
responsible for the observed changes in ac-
tivity. In those cases where inhibitors were
available, we verified the band identity in
additional studies by inhibiting probe labeling
as described in Materials and Methods (data
not shown).
Table 1 lists the identified proteins that
exhibited significantly altered activity between
tumor and normal tissues. When more than
one protein was identified within a band, they
were listed as “and/or.” The majority of the
protein activities that changed were elevated
in tumor relative to normal colon tissues. In
contrast, the highly related carboxylesterases
of 50–60 kDa had distinctly decreased activity
in tumors, comprising two of the three protein
bands observed to have lower activities. To
our knowledge, only five of the differentially
active proteins (Table 1, bold highlighted)
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Fig. 1. AX5070, activity-based serine hydrolase probe.
AX5070 consisted of a fluorophosphonate reactive
group, an alkyl linker, and a fluorescent tetramethyl-
rhodamine tag.
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Fig. 2. Serine hydrolase activity profiles of clinical normal (N) and tumor (T) colon tissue proteomes. Repre-
sentative in-gel fluorescence of serine hydrolase activities from (A) soluble and from (B) deglycosylated mem-
brane fractions of clinical proteomes labeled with AX5070. The tumor (T) or adjacent normal (N) colon
tissues were numbered 1–12, in which patients 1–6 and 7–12 have been diagnosed with stage II and III col-
orectal adenocarcinoma, respectively. The green arrowheads indicate proteins whose activities were higher in
tumors vs normal tissues, whereas blue arrowheads indicate lower activities.
Fig. 3.Total protein staining of clinical normal (N) and tumor (T) colon tissue proteomes. The gels of (A) sol-
uble and of (B) deglycosylated membrane fractions of clinical proteomes represented in Fig. 2 were stained
for total protein expression using Coomassie blue.The tumor (T) or adjacent normal (N) colon tissues were
numbered 1–12, in which patients 1–6 and 7–12 have been diagnosed with stage II and III colorectal adeno-
carcinoma, respectively. Twenty micrograms of total protein were loaded per gel lane.
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Table 1
Serine Hydrolases That Exhibited Significant
Changes in Activity in Clinical Tumor vs 
Normal Colon Tissues
Soluble proteins: increased activity in tumor
Fatty acid synthase (4.1)
Dipeptidyl peptidase IV (4.9)
Prolyl endopeptidase (2.3)
N-acylaminoacyl-peptide hydrolase (2.9)
Cytosolic acyl coA thioester hydrolase 
and/or
Platelet-activating factor acetylhydrolase 
II (2.6)
Platelet-activating factor acetylhydrolase Ib -
and -subunits (1.9)
Acylprotein thioestrase I/Lysophospholipase II
(2.1)
Membrane Proteins: increased activity in tumor
Fibroblast activation protein (23)
Membrane Proteins: decreased activity in tumor
Carboxylesterase hCE2 (0.7)
Carboxylesterases ACAT, HUMCOXYSB,
HSSE1, HUMLCEA, and/or HBR3 (0.5)
Activity was measured as fluorescence volume
units in the identified protein bands. The ratio of the
average activity values of 12 colon tumors and of 12
matched-patient normal colon tissues is calculated
and presented in parentheses (T:N). Proteins that
have been previously associated with cancer in the lit-
erature are highlighted in bold.
have been previously reported in the literature
to play a role in human cancer: fatty acid
synthase, dipeptidyl peptidase IV (DPP-IV),
prolyl endopeptidase (PEP), FAP, and car-
boxylesterase 2 (hCE2). We are currently ascer-
taining the identities of the other protein
bands that displayed differential activity.
These were proteins that were generally of
very low activity that approached the limits of
detection (femtomole) for the mass spectrom-
eter, or were identified but could not be dis-
tinguished from among other proteins of
similar molecular weight.
Fibroblast Activation Protein
Of the proteins that displayed elevated
activity in tumor tissues and very low-to-
absent activity in patient-matched, adjacent
normal tissues, the integral membrane protein
FAP was the most distinguishable. Mass spec-
trometry confirmed that FAP was the only
protein in the band of interest. Notably, the
average tumor-to-normal activity ratios for
FAP were 1.5- to 3.5-fold higher in stage III
(patients 7–12) vs stage II (patients 1–6) carci-
noma in three repeat experiments, giving an
overall increase of 2.3-fold (Fig. 4A). In com-
paring stages, the number of subjects in each
group decreased from n = 12 to n = 6, result-
ing in a loss of statistical power. Nevertheless,
this trend appears to be the first indication
that FAP activity may increase with tumor
progression.
The activities of N-acylaminoacyl-peptide
hydrolase and PEP characteristically flank FAP
near 75 kDa when the membrane sample is
deglycosylated (Fig. 4B). We have observed
and verified this feature in multiple tissue
types and cell lines (data not shown), making
for a convenient assessment of FAP activity.
We next determined whether the increased
FAP activity in the tumor samples was associ-
ated with increased protein expression. The
low amount of FAP protein was not detectable
with Coomassie blue staining; therefore, FAP
expression was measured by Western blot
using the F19 antibody (Fig. 4C). In initial
experiments, we found that the monoclonal
F19 antibody recognized deglycosylated FAP
very poorly and we therefore used native
membrane proteome for the Western blot.
Under these conditions, the denatured, glyco-
sylated FAP subunit is 97 kDa. Similar to FAP
activity (Fig. 4B), FAP protein expression (Fig.
4C) was found to be higher in stage III tumor
samples as compared with stage II, and there
was no detectable signal in the normal tissue
samples. We were able to correlate FAP activity
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(by probe labeling) to FAP expression (by
Western blot) with r = 0.94, indicating that the
increase in activity arises entirely from an
increase in protein expression.
Discussion
It has become increasingly evident that the
development of cancer results from a multi-
tude of different cell types acting in concert to
optimize tumor progression and survival (4).
Stromal cells, including fibroblasts, have been
reported to make up as much as 90% of the
tumor mass, whereas other cell types such as
leukocytes and macrophages are known to
infiltrate tumors and contribute to the tumor
environment. All of these cells have dynamic
enzymatic activities; for example, activated
fibroblasts are known to acquire the expression
of proteolytic enzymes such as matrix metal-
loproteinases and urokinase plasminogen acti-
vator (reviewed by Martin [5] and Schurch
[6]). Given such complexities, the search for
novel tumor targets must rely on unbiased
and global methods of analysis.
ABPP is well suited to sifting through com-
plex proteomes such as tumors. It reports only
on protein activity, is exquisitely sensitive, and
allows for the analysis of membrane proteins.
For screening, only about 20 g of protein is
required for activity analysis. Furthermore,
ABPP limits the class of proteins to that clas-
sified by the probe (e.g., serine hydrolases,
metalloproteinases, kinases), therefore pro-
ducing a manageable but significant set of
results. This aspect is also advantageous for
rapidly classifying novel proteins.
Fig. 4. Fibroblast activated protein (FAP) is increased in tumor (T) relative to normal (N) colon tissues in a
stage-dependent manner. Tumor membrane proteomes from patients with stage III cancer (T7–T12) displayed
a trend of having higher FAP activity as compared with those with stage II cancer (T1–T6) as measured by
AX5070 labeling. (A) The relative activity (fluorescence) of FAP is graphically depicted to highlight the approx-
imately twofold higher activity in patients with stage III cancer. Dashed lines indicate the average values. Closed
circles represent FAP; open squares and triangles represent N-acylaminoacyl-peptide hydrolase (APH) and
prolyl endopeptidase (PEP) activities, respectively, as measured in the membrane proteome fraction. (B) Shown
is a grayscale depiction of the in-gel fluorescence of the deglycosylated membrane proteome region where FAP
characteristically migrates, flanked by APH and PEP. There was minimal FAP activity in the normal tissues. (C)
The amount of FAP protein expression was determined by Western blot of native membrane proteomes.
The amount of FAP protein was found to be increased in patients with more advanced cancer, similar to that
seen for FAP activity. Shown are representative data from three repeat experiments.
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In this report, we applied ABPP toward the
discovery of possible drug target enzymes 
in human clinical colorectal adenocarcinoma
using a small pilot set of matched tissues.
From the large protein superfamily, the serine
hydrolases, a number of active enzymes were
identified, a subset of which showed differ-
ential activity between tumor and normal 
tissues. One of these proteins, fatty acid syn-
thase, has long been known to be overex-
pressed in tumors, and inhibitors have been
developed that have shown antitumor activity
(7,8). In contrast, we also identified elevated
serine hydrolase activities that are not well
associated with cancer, such as DPP-IV and
PEP. These enzymes are currently pursued as
targets for type 2 diabetes and memory loss,
respectively (9–12), with scant reports of their
increases in cancer (13,14). Nevertheless, their
roles as peptidases make them attractive tar-
gets for new indications.
The selective expression of FAP in tumors,
specifically in stromal fibroblasts, was initially
recognized using qualitative immunohisto-
chemistry methods (15). It is not detected in
normal adult tissues. Recently, methods have
been devised to quantitatively measure FAP’s
activity by either immunocapturing FAP from
a cellular lysate prior to adding a fluorogenic
substrate (16), or by measuring FAP’s abil-
ity to degrade 3H-gelatin (17). Using ABPP,
we detected a twofold increase in the relative
ratio of FAP activity in patients with more
advanced clinical disease, a finding that is
suggestive of an involvement in cancer pro-
gression. We were able to measure the FAP
activity directly and quantitatively without
prior purification because FAP appears as a
very distinct band on SDS-PAGE after degly-
cosylation. This represents an advance in the
detection of FAP and may serve as a paradigm
for other proteins. Immunocapture-based
methods may not be optimally specific or
quantitative. DPP-IV has been demonstrated
to form heteromeric dimers with FAP (18,19).
Therefore, immunoprecipitation of FAP could
potentially precipitate DPP-IV as well, result-
ing in an overestimation of dipeptidyl pep-
tidase activity. Immunocapture may also
precipitate other FAP-associated proteins with
prolylpeptidase activity. As FAP has been
observed in high-molecular-weight complexes
of 400,000 kDa, this possibility may exist
(20). Finally, in order for the immunocapture
methods to be accurate, the antibody must
capture all of the FAP in the proteome or at
least capture consistently from proteome to
proteome. Incomplete immunocapture could
lead to an underestimation of activity. Because
activity-based probes label at the active site,
the activity reflects that of the protein of inter-
est alone. The only circumstance when this is
not true occurs when multiple protein activi-
ties share the same molecular weight and
cannot be discerned by one-dimensional SDS-
PAGE. In those infrequent instances, the use
of selective inhibitors, two-dimensional gels,
or peptide-based profiling (21) can resolve the
identity.
Of several carboxylesterases, hCE2 has been
recognized as the key enzyme that converts
the chemotherapy prodrug irinotecan to the
active cytotoxic metabolite, SN-38 (22,23). It is
also the only carboxylesterase whose gene and
protein expressions correlate with irinotecan-
hydrolyzing activity (22,24). Interestingly, a
number of investigators have found hCE2
expression and activity to be lower in tumor
relative to normal tissues, despite the use of
irinotecan as a common treatment for ad-
vanced colorectal cancer (25,26). Using activity-
based proteomic profiling, we also observed
hCE2 activity to be 50% lower in colorectal
tumors compared with adjacent normal tissue,
corroborating previous reports.
We identified several protein activities that
were elevated in tumor compared with nor-
mal colon tissues that had not been previously
recognized to have an association with cancer.
Of these, a particularly interesting finding was
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the approximately twofold increase in the
activities of PAF-AHs Ib and II, two intracel-
lular phospholipase A2 enzymes that serve
distinct functions (reviewed by Stafforini [27]
and Arai [28]). PAF-AH Ib regulates the levels
of PAF, a phospholipid that mediates a broad
range of immune and allergic reactions. In
contrast, PAF-AH II scavenges oxidatively
fragmented phospholipids and can protect
against oxidative stress-induced apoptosis. To
our knowledge, neither of these has been
implicated with a role in cancer, although it is
not difficult to imagine an involvement of
immune reactivity and oxidative stress within
the tumor environment. Intriguingly, the activ-
ity of the secreted plasma isoform of PAF-AH
(which has homology with intracellular iso-
form II) was recently reported to be increased
in the plasma of patients with colorectal
cancer (29).
There were a few protein activities that we
did not observe in these samples that may
have been expected, for example, urokinase
plasminogen activator (uPA). Because we have
seen AX5070 label uPA in other samples 
such as human umbilical vein endothelial
cells, it is likely that we did not identify it
because it was not very active in the clinical
colon samples.
The present study highlights the powerful
application of ABPP toward the examination
of clinical tumor tissues, complex proteomes
that are available in only scarce quantities but
that are most informative for target discovery.
Protein activities that are increased in tumor
relative to normal tissues are possible drug
targets, whose inhibition may produce antitu-
mor effects. Approximately half of such pro-
tein activities identified in this study have
already been validated in the literature to have
an association with cancer. It is probable that
additional studies will further implicate the
other half to also play a role. Because the pro-
teins identified by ABPP are based on reactiv-
ity with small molecules, they should prove to
be “druggable” via inhibition of the active site.
ABPP can further be used to screen for the
effectiveness and specificity of drug inhibition,
potentially shortening the drug development
process.
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